Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Wisconsin: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 85 | 5,769 | 47% |
| 2020 | 79 | 5,018 | 49% |
| 2021 | 88 | 5,706 | 53% |
| 2022 | 96 | 5,490 | 56% |
| 2023 | 104 | 5,661 | 59% |
| 2024 | 107 | 5,630 | 61% |
| 2025 from claims | – | 5,663 5,197–5,992 | 61% |
| 2026 forecast | – | 5,948 5,234–6,864 | 61% |
| 2027 forecast | – | 6,100 5,215–7,270 | 61% |
| 2028 forecast | – | 6,256 5,220–7,660 | 61% |
| 2029 forecast | – | 6,414 5,239–8,044 | 62% |
| 2030 forecast | – | 6,576 5,268–8,427 | 62% |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 28% of the cases CMS names in Wisconsin; 58 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 55% hospital outpatient, 34% surgery center, 10% office. The share outside the hospital has moved −12 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 165 | 12,036+1%/yr | +1%/yr | 8.4 | 66% | 13,800 in 2030+2.3%/yr |
| Ohio | 179 | 10,830−5.3%/yr | −5.3%/yr | 9.3 | 43% | 11,600 in 2030+1.2%/yr |
| Michigan | 128 | 7,269−3.7%/yr | −3.7%/yr | 8.1 | 75% | 8,240 in 2030+2.1%/yr |
| Indiana | 117 | 6,614−1.7%/yr | −1.7%/yr | 9.0 | 71% | 8,050 in 2030+3.3%/yr |
| Missouri | 93 | 6,170+1.6%/yr | +1.6%/yr | 9.5 | 28% | 8,640 in 2030+5.8%/yr |
| Minnesota | 88 | 4,824+0.9%/yr | +0.9%/yr | 10.1 | 73% | 6,880 in 2030+6.1%/yr |
| Kansas | 57 | 3,413+4%/yr | +4%/yr | 8.2 | 46% | 4,450 in 2030+4.5%/yr |
| Nebraska | 37 | 2,646+7.2%/yr | +7.2%/yr | 9.8 | 71% | 4,000 in 2030+7.1%/yr |
| Iowa | 36 | 2,386+2.2%/yr | +2.2%/yr | 5.2 | 62% | 2,800 in 2030+2.7%/yr |
| South Dakota | 16 | 1,153−1.6%/yr | −1.6%/yr | 8.6 | 12% | 1,270 in 2030+1.6%/yr |
| North Dakota | 12 | 670−3.9%/yr | −3.9%/yr | 6.5 | 37% | 740 in 2030+1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 8 | 775+8.3%/yr | +8.3%/yr | 1.31.2× | 50% | 1,500 in 2030+12%/yr |
| Spinal cord & DRG stimulation | 10 | 363−4.6%/yr | −4.6%/yr | 0.60.8× | 50% | 420 in 2030+2.4%/yr |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Wisconsin · Every state · Compare with Illinois
Avanos Medical leads with 37% of company spending on these surgeons in 2025, −11 pts on 2024.
In 2025, 7 companies reported engagement with Wisconsin’s surgeons worth $94K in consulting, speaking, meals and travel tied to these products, about $875 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.